# PeptideScanner evidence objects: Nesiritide

Every published version of the records placed with Nesiritide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/nesiritide.json. Selected public evidence only; not medical advice.

- Objects: 56
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00091520-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00091520

> PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00091520-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-05-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00091520-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00091520-nesiritide-v1
- Content SHA-256: `d762550de12d368522c7ba5cea823af48213f3b61265f55ced84dc49c76accad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00091520 ([`ctg-observation-nct00091520-2011-05-20-7cb217c64bcd`](#source-ctg-observation-nct00091520-2011-05-20-7cb217c64bcd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00091520-2011-05-20-7cb217c64bcd`](#source-ctg-observation-nct00091520-2011-05-20-7cb217c64bcd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00091520-2011-05-20-7cb217c64bcd`](#source-ctg-observation-nct00091520-2011-05-20-7cb217c64bcd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00091520-2011-05-20-7cb217c64bcd`](#source-ctg-observation-nct00091520-2011-05-20-7cb217c64bcd))

### Sources

<a id="source-ctg-observation-nct00091520-2011-05-20-7cb217c64bcd"></a>
- **ClinicalTrials.gov record NCT00091520 · retained source version 2011-05-20:7cb217c64bcd2c57e7417e22a38f9f2f4c023974de2153abf22b4ae20442556e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00091520) (`ctg-observation-nct00091520-2011-05-20-7cb217c64bcd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00091520." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00091520-nesiritide-v1 SHA-256: d762550de12d368522c7ba5cea823af48213f3b61265f55ced84dc49c76accad.

---

<a id="clinicaltrials-gov-nct00119691-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00119691

> PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00119691-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-09-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00119691-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00119691-nesiritide-v1
- Content SHA-256: `1bab4f8649a0113975de22191a7db6996a5cff8a4453c7da71b5a941e1fd4ace`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00119691 ([`ctg-observation-nct00119691-2013-09-12-cff429b02bde`](#source-ctg-observation-nct00119691-2013-09-12-cff429b02bde))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00119691-2013-09-12-cff429b02bde`](#source-ctg-observation-nct00119691-2013-09-12-cff429b02bde))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00119691-2013-09-12-cff429b02bde`](#source-ctg-observation-nct00119691-2013-09-12-cff429b02bde))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00119691-2013-09-12-cff429b02bde`](#source-ctg-observation-nct00119691-2013-09-12-cff429b02bde))

### Sources

<a id="source-ctg-observation-nct00119691-2013-09-12-cff429b02bde"></a>
- **ClinicalTrials.gov record NCT00119691 · retained source version 2013-09-12:cff429b02bdefdb0448a313ea43a4629c47f740712a3e3ba454f5895d1ddd4be** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00119691) (`ctg-observation-nct00119691-2013-09-12-cff429b02bde`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00119691." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00119691-nesiritide-v1 SHA-256: 1bab4f8649a0113975de22191a7db6996a5cff8a4453c7da71b5a941e1fd4ace.

---

<a id="clinicaltrials-gov-nct00170183-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00170183

> PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00170183-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00170183-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00170183-nesiritide-v1
- Content SHA-256: `96477203c9b33818bc5442ede033f6f66c0a5c75eeb5acc0866704934afae5d4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00170183 ([`ctg-observation-nct00170183-2009-11-16-88deadbebed7`](#source-ctg-observation-nct00170183-2009-11-16-88deadbebed7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00170183-2009-11-16-88deadbebed7`](#source-ctg-observation-nct00170183-2009-11-16-88deadbebed7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00170183-2009-11-16-88deadbebed7`](#source-ctg-observation-nct00170183-2009-11-16-88deadbebed7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00170183-2009-11-16-88deadbebed7`](#source-ctg-observation-nct00170183-2009-11-16-88deadbebed7))

### Sources

<a id="source-ctg-observation-nct00170183-2009-11-16-88deadbebed7"></a>
- **ClinicalTrials.gov record NCT00170183 · retained source version 2009-11-16:88deadbebed7fa333fc6353ef80889df6d59a4188afabd0a8080a39a866a481e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00170183) (`ctg-observation-nct00170183-2009-11-16-88deadbebed7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00170183." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00170183-nesiritide-v1 SHA-256: 96477203c9b33818bc5442ede033f6f66c0a5c75eeb5acc0866704934afae5d4.

---

<a id="clinicaltrials-gov-nct00205426-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00205426

> PeptideScanner retained ClinicalTrials.gov record NCT00205426 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-10-14, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00205426-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-10-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00205426-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00205426-nesiritide-v1
- Content SHA-256: `53be2d893dcb5156b50ea8636474615f20292b51c2170fc1b533feeedb6d4db8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00205426 ([`ctg-observation-nct00205426-2015-10-14-7208005ae145`](#source-ctg-observation-nct00205426-2015-10-14-7208005ae145))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00205426 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-10-14, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00205426-2015-10-14-7208005ae145`](#source-ctg-observation-nct00205426-2015-10-14-7208005ae145))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00205426 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-10-14, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00205426-2015-10-14-7208005ae145`](#source-ctg-observation-nct00205426-2015-10-14-7208005ae145))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00205426-2015-10-14-7208005ae145`](#source-ctg-observation-nct00205426-2015-10-14-7208005ae145))

### Sources

<a id="source-ctg-observation-nct00205426-2015-10-14-7208005ae145"></a>
- **ClinicalTrials.gov record NCT00205426 · retained source version 2015-10-14:7208005ae1451ab83202871999a9f9f30b30679473ef43f1af16e5df10a01312** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00205426) (`ctg-observation-nct00205426-2015-10-14-7208005ae145`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00205426." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00205426-nesiritide-v1 SHA-256: 53be2d893dcb5156b50ea8636474615f20292b51c2170fc1b533feeedb6d4db8.

---

<a id="clinicaltrials-gov-nct00252187-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00252187

> PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00252187-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-12-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00252187-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00252187-nesiritide-v1
- Content SHA-256: `9a279a29472f99e54179619866762c83b27701775970f4c8dd80df33853ef8f7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00252187 ([`ctg-observation-nct00252187-2012-12-20-c724f8ed0283`](#source-ctg-observation-nct00252187-2012-12-20-c724f8ed0283))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00252187-2012-12-20-c724f8ed0283`](#source-ctg-observation-nct00252187-2012-12-20-c724f8ed0283))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00252187 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-12-20, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00252187-2012-12-20-c724f8ed0283`](#source-ctg-observation-nct00252187-2012-12-20-c724f8ed0283))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00252187-2012-12-20-c724f8ed0283`](#source-ctg-observation-nct00252187-2012-12-20-c724f8ed0283))

### Sources

<a id="source-ctg-observation-nct00252187-2012-12-20-c724f8ed0283"></a>
- **ClinicalTrials.gov record NCT00252187 · retained source version 2012-12-20:c724f8ed02839f04fa5fe6964c02c186270cf83243e5e6119a317257c1b32b2a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00252187) (`ctg-observation-nct00252187-2012-12-20-c724f8ed0283`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00252187." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00252187-nesiritide-v1 SHA-256: 9a279a29472f99e54179619866762c83b27701775970f4c8dd80df33853ef8f7.

---

<a id="clinicaltrials-gov-nct00270361-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00270361

> PeptideScanner retained ClinicalTrials.gov record NCT00270361 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-07-26, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00270361-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-07-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00270361-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270361-nesiritide-v1
- Content SHA-256: `ba48d391d37dbfb9f1a51b0be4a8cf04e38fc2fe1700ce03a777383029158a7c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00270361 ([`ctg-observation-nct00270361-2011-07-26-c11713b16719`](#source-ctg-observation-nct00270361-2011-07-26-c11713b16719))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00270361 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-07-26, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270361-2011-07-26-c11713b16719`](#source-ctg-observation-nct00270361-2011-07-26-c11713b16719))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00270361 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-07-26, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270361-2011-07-26-c11713b16719`](#source-ctg-observation-nct00270361-2011-07-26-c11713b16719))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00270361-2011-07-26-c11713b16719`](#source-ctg-observation-nct00270361-2011-07-26-c11713b16719))

### Sources

<a id="source-ctg-observation-nct00270361-2011-07-26-c11713b16719"></a>
- **ClinicalTrials.gov record NCT00270361 · retained source version 2011-07-26:c11713b167195f463c6e4c0fc5495f7011a8b56b5a2ceaad22cdac9fdccd32df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00270361) (`ctg-observation-nct00270361-2011-07-26-c11713b16719`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00270361." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270361-nesiritide-v1 SHA-256: ba48d391d37dbfb9f1a51b0be4a8cf04e38fc2fe1700ce03a777383029158a7c.

---

<a id="clinicaltrials-gov-nct00270374-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00270374

> PeptideScanner retained ClinicalTrials.gov record NCT00270374 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00270374-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-06-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00270374-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270374-nesiritide-v1
- Content SHA-256: `e5a8412a83892d9f0ed24a143a2db89b286837f39d0d6c4352255440d0796783`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00270374 ([`ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a`](#source-ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00270374 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a`](#source-ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00270374 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a`](#source-ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a`](#source-ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a))

### Sources

<a id="source-ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a"></a>
- **ClinicalTrials.gov record NCT00270374 · retained source version 2011-06-10:ade7e47d7d8ab36bd11ce7560b2f177a1a1a154a24f2da6def564e9f7534eb00** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00270374) (`ctg-observation-nct00270374-2011-06-10-ade7e47d7d8a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00270374." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270374-nesiritide-v1 SHA-256: e5a8412a83892d9f0ed24a143a2db89b286837f39d0d6c4352255440d0796783.

---

<a id="clinicaltrials-gov-nct00270400-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00270400

> PeptideScanner retained ClinicalTrials.gov record NCT00270400 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00270400-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-06-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00270400-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270400-nesiritide-v1
- Content SHA-256: `5f0b23ba37c875f1df3bc77095f5d667b7cda356f5c72689453faf217068c2e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00270400 ([`ctg-observation-nct00270400-2011-06-10-4e64b8f064d3`](#source-ctg-observation-nct00270400-2011-06-10-4e64b8f064d3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00270400 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270400-2011-06-10-4e64b8f064d3`](#source-ctg-observation-nct00270400-2011-06-10-4e64b8f064d3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00270400 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00270400-2011-06-10-4e64b8f064d3`](#source-ctg-observation-nct00270400-2011-06-10-4e64b8f064d3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00270400-2011-06-10-4e64b8f064d3`](#source-ctg-observation-nct00270400-2011-06-10-4e64b8f064d3))

### Sources

<a id="source-ctg-observation-nct00270400-2011-06-10-4e64b8f064d3"></a>
- **ClinicalTrials.gov record NCT00270400 · retained source version 2011-06-10:4e64b8f064d35bb9e8c1bb11c02df322406a8240e335d0c4320410598fbee5a4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00270400) (`ctg-observation-nct00270400-2011-06-10-4e64b8f064d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00270400." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00270400-nesiritide-v1 SHA-256: 5f0b23ba37c875f1df3bc77095f5d667b7cda356f5c72689453faf217068c2e3.

---

<a id="clinicaltrials-gov-nct00271557-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00271557

> PeptideScanner retained ClinicalTrials.gov record NCT00271557 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-03-04, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00271557-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-03-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00271557-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00271557-nesiritide-v1
- Content SHA-256: `5b0d56d703445bee1632e441f002836a7091a6ed511a1b2e54aeba69aeb8b66b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00271557 ([`ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f`](#source-ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00271557 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-03-04, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f`](#source-ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00271557 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-03-04, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f`](#source-ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f`](#source-ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f))

### Sources

<a id="source-ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f"></a>
- **ClinicalTrials.gov record NCT00271557 · retained source version 2011-03-04:1d72bcb03b8fa958551b440569b3174d4e487f4c8616b0b2ccbaf170917e5aed** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00271557) (`ctg-observation-nct00271557-2011-03-04-1d72bcb03b8f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00271557." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00271557-nesiritide-v1 SHA-256: 5b0d56d703445bee1632e441f002836a7091a6ed511a1b2e54aeba69aeb8b66b.

---

<a id="clinicaltrials-gov-nct00288730-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00288730

> PeptideScanner retained ClinicalTrials.gov record NCT00288730 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00288730-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-06-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00288730-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00288730-nesiritide-v1
- Content SHA-256: `8c9bc117cb60e469201e9bddea69a3d1f5dec41457d49d58862d5cccf840aabf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00288730 ([`ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1`](#source-ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00288730 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1`](#source-ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00288730 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-06-10, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1`](#source-ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1`](#source-ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1))

### Sources

<a id="source-ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1"></a>
- **ClinicalTrials.gov record NCT00288730 · retained source version 2011-06-10:abe4c83fc6b1cbe0a27e5afd53053cb880ea78545a1694998c38481860a6e3a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00288730) (`ctg-observation-nct00288730-2011-06-10-abe4c83fc6b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00288730." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00288730-nesiritide-v1 SHA-256: 8c9bc117cb60e469201e9bddea69a3d1f5dec41457d49d58862d5cccf840aabf.

---

<a id="clinicaltrials-gov-nct00387621-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00387621

> PeptideScanner retained ClinicalTrials.gov record NCT00387621 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-05-17, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00387621-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2012-05-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00387621-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00387621-nesiritide-v1
- Content SHA-256: `0f37e372477d79b47a926896f4a06202bde9ab42847da1c81ec3dc0f770f6375`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00387621 ([`ctg-observation-nct00387621-2012-05-17-1fba2cb07789`](#source-ctg-observation-nct00387621-2012-05-17-1fba2cb07789))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00387621 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-05-17, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00387621-2012-05-17-1fba2cb07789`](#source-ctg-observation-nct00387621-2012-05-17-1fba2cb07789))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00387621 at 2026-11-16T01:39:41.882Z. Its registry update date was 2012-05-17, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00387621-2012-05-17-1fba2cb07789`](#source-ctg-observation-nct00387621-2012-05-17-1fba2cb07789))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00387621-2012-05-17-1fba2cb07789`](#source-ctg-observation-nct00387621-2012-05-17-1fba2cb07789))

### Sources

<a id="source-ctg-observation-nct00387621-2012-05-17-1fba2cb07789"></a>
- **ClinicalTrials.gov record NCT00387621 · retained source version 2012-05-17:1fba2cb077896dfaad3108d01417db0f73fdae7f97fb9937248669f075300661** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00387621) (`ctg-observation-nct00387621-2012-05-17-1fba2cb07789`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00387621." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00387621-nesiritide-v1 SHA-256: 0f37e372477d79b47a926896f4a06202bde9ab42847da1c81ec3dc0f770f6375.

---

<a id="clinicaltrials-gov-nct00405548-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00405548

> PeptideScanner retained ClinicalTrials.gov record NCT00405548 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-07-01, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00405548-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-07-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00405548-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00405548-nesiritide-v1
- Content SHA-256: `e5972d75c69569f00941b404e1a582dfeb791f1235d3012d767e04b89837a8ab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00405548 ([`ctg-observation-nct00405548-2015-07-01-f378d96a9709`](#source-ctg-observation-nct00405548-2015-07-01-f378d96a9709))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00405548 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-07-01, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00405548-2015-07-01-f378d96a9709`](#source-ctg-observation-nct00405548-2015-07-01-f378d96a9709))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00405548 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-07-01, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00405548-2015-07-01-f378d96a9709`](#source-ctg-observation-nct00405548-2015-07-01-f378d96a9709))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00405548-2015-07-01-f378d96a9709`](#source-ctg-observation-nct00405548-2015-07-01-f378d96a9709))

### Sources

<a id="source-ctg-observation-nct00405548-2015-07-01-f378d96a9709"></a>
- **ClinicalTrials.gov record NCT00405548 · retained source version 2015-07-01:f378d96a9709396485343e720cd9e51ebc01dc56994438db38a8446beeb872b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00405548) (`ctg-observation-nct00405548-2015-07-01-f378d96a9709`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00405548." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00405548-nesiritide-v1 SHA-256: e5972d75c69569f00941b404e1a582dfeb791f1235d3012d767e04b89837a8ab.

---

<a id="clinicaltrials-gov-nct00405639-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00405639

> PeptideScanner retained ClinicalTrials.gov record NCT00405639 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-03-17, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00405639-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-03-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00405639-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00405639-nesiritide-v1
- Content SHA-256: `e23b9cbfc4aa98d04ed19e675a087eb13fb43dffe54a82f176ca1c994cc04651`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00405639 ([`ctg-observation-nct00405639-2014-03-17-ffc6d64b9856`](#source-ctg-observation-nct00405639-2014-03-17-ffc6d64b9856))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00405639 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-03-17, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00405639-2014-03-17-ffc6d64b9856`](#source-ctg-observation-nct00405639-2014-03-17-ffc6d64b9856))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00405639 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-03-17, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00405639-2014-03-17-ffc6d64b9856`](#source-ctg-observation-nct00405639-2014-03-17-ffc6d64b9856))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00405639-2014-03-17-ffc6d64b9856`](#source-ctg-observation-nct00405639-2014-03-17-ffc6d64b9856))

### Sources

<a id="source-ctg-observation-nct00405639-2014-03-17-ffc6d64b9856"></a>
- **ClinicalTrials.gov record NCT00405639 · retained source version 2014-03-17:ffc6d64b9856dd020430bf8335a89b3971f74b0dd224254356955fc104328fa2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00405639) (`ctg-observation-nct00405639-2014-03-17-ffc6d64b9856`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00405639." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00405639-nesiritide-v1 SHA-256: e23b9cbfc4aa98d04ed19e675a087eb13fb43dffe54a82f176ca1c994cc04651.

---

<a id="clinicaltrials-gov-nct00475852-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00475852

> PeptideScanner retained ClinicalTrials.gov record NCT00475852 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00475852-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-03-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00475852-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00475852-nesiritide-v1
- Content SHA-256: `83364960bc1f42d7222e30e2a3d2c800634cc8c3122bd63ad55e4b80da3d6907`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00475852 ([`ctg-observation-nct00475852-2013-03-08-dd22afdc2231`](#source-ctg-observation-nct00475852-2013-03-08-dd22afdc2231))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00475852 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00475852-2013-03-08-dd22afdc2231`](#source-ctg-observation-nct00475852-2013-03-08-dd22afdc2231))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00475852 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-03-08, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00475852-2013-03-08-dd22afdc2231`](#source-ctg-observation-nct00475852-2013-03-08-dd22afdc2231))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00475852-2013-03-08-dd22afdc2231`](#source-ctg-observation-nct00475852-2013-03-08-dd22afdc2231))

### Sources

<a id="source-ctg-observation-nct00475852-2013-03-08-dd22afdc2231"></a>
- **ClinicalTrials.gov record NCT00475852 · retained source version 2013-03-08:dd22afdc2231114796cd544cbdf3e6a548d3a204283886943f80f1e98eafb095** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00475852) (`ctg-observation-nct00475852-2013-03-08-dd22afdc2231`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00475852." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00475852-nesiritide-v1 SHA-256: 83364960bc1f42d7222e30e2a3d2c800634cc8c3122bd63ad55e4b80da3d6907.

---

<a id="clinicaltrials-gov-nct00559338-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00559338

> PeptideScanner retained ClinicalTrials.gov record NCT00559338 at 2026-11-16T01:39:41.882Z. Its registry update date was 2007-11-16, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00559338-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2007-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00559338-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00559338-nesiritide-v1
- Content SHA-256: `b8e336cdaba9e4fdeed71c197ca28861943e07255c0544bf6980233535377f1a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00559338 ([`ctg-observation-nct00559338-2007-11-16-fb117904fc07`](#source-ctg-observation-nct00559338-2007-11-16-fb117904fc07))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00559338 at 2026-11-16T01:39:41.882Z. Its registry update date was 2007-11-16, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00559338-2007-11-16-fb117904fc07`](#source-ctg-observation-nct00559338-2007-11-16-fb117904fc07))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00559338 at 2026-11-16T01:39:41.882Z. Its registry update date was 2007-11-16, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00559338-2007-11-16-fb117904fc07`](#source-ctg-observation-nct00559338-2007-11-16-fb117904fc07))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00559338-2007-11-16-fb117904fc07`](#source-ctg-observation-nct00559338-2007-11-16-fb117904fc07))

### Sources

<a id="source-ctg-observation-nct00559338-2007-11-16-fb117904fc07"></a>
- **ClinicalTrials.gov record NCT00559338 · retained source version 2007-11-16:fb117904fc07199163f3e8ca7028505b76b6cbe9147b2f85b3aee739ee438939** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00559338) (`ctg-observation-nct00559338-2007-11-16-fb117904fc07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00559338." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00559338-nesiritide-v1 SHA-256: b8e336cdaba9e4fdeed71c197ca28861943e07255c0544bf6980233535377f1a.

---

<a id="clinicaltrials-gov-nct00573144-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00573144

> PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00573144-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-09-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00573144-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00573144-nesiritide-v1
- Content SHA-256: `e93824ad8712abe370193ca28189b278fda62d0e1f1ddcac4d674084eeb222b7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00573144 ([`ctg-observation-nct00573144-2014-09-09-f5a37a6bd340`](#source-ctg-observation-nct00573144-2014-09-09-f5a37a6bd340))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00573144-2014-09-09-f5a37a6bd340`](#source-ctg-observation-nct00573144-2014-09-09-f5a37a6bd340))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00573144-2014-09-09-f5a37a6bd340`](#source-ctg-observation-nct00573144-2014-09-09-f5a37a6bd340))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00573144-2014-09-09-f5a37a6bd340`](#source-ctg-observation-nct00573144-2014-09-09-f5a37a6bd340))

### Sources

<a id="source-ctg-observation-nct00573144-2014-09-09-f5a37a6bd340"></a>
- **ClinicalTrials.gov record NCT00573144 · retained source version 2014-09-09:f5a37a6bd340a57cbc2f06f659ffb8518d74b62d8928867d6193f8fcebf96e7e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00573144) (`ctg-observation-nct00573144-2014-09-09-f5a37a6bd340`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00573144." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00573144-nesiritide-v1 SHA-256: e93824ad8712abe370193ca28189b278fda62d0e1f1ddcac4d674084eeb222b7.

---

<a id="clinicaltrials-gov-nct00653042-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00653042

> PeptideScanner retained ClinicalTrials.gov record NCT00653042 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00653042-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-05-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00653042-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00653042-nesiritide-v1
- Content SHA-256: `e09937469118d88d4f47373f46877199d7e0b2d1e169cf4d8a71061640053ca3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00653042 ([`ctg-observation-nct00653042-2011-05-19-adb83015adc9`](#source-ctg-observation-nct00653042-2011-05-19-adb83015adc9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00653042 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00653042-2011-05-19-adb83015adc9`](#source-ctg-observation-nct00653042-2011-05-19-adb83015adc9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00653042 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00653042-2011-05-19-adb83015adc9`](#source-ctg-observation-nct00653042-2011-05-19-adb83015adc9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00653042-2011-05-19-adb83015adc9`](#source-ctg-observation-nct00653042-2011-05-19-adb83015adc9))

### Sources

<a id="source-ctg-observation-nct00653042-2011-05-19-adb83015adc9"></a>
- **ClinicalTrials.gov record NCT00653042 · retained source version 2011-05-19:adb83015adc991d8c6ad93539a22c78376dcea62c07ffb11ceb539bc07e584e6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00653042) (`ctg-observation-nct00653042-2011-05-19-adb83015adc9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00653042." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00653042-nesiritide-v1 SHA-256: e09937469118d88d4f47373f46877199d7e0b2d1e169cf4d8a71061640053ca3.

---

<a id="clinicaltrials-gov-nct00813202-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00813202

> PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00813202-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-02-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00813202-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00813202-nesiritide-v1
- Content SHA-256: `7bbd049b7981b227cab56ccc5bdcf2ea09138cecfd9329139efa2e814f6948f5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00813202 ([`ctg-observation-nct00813202-2014-02-28-d5279995f34f`](#source-ctg-observation-nct00813202-2014-02-28-d5279995f34f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00813202-2014-02-28-d5279995f34f`](#source-ctg-observation-nct00813202-2014-02-28-d5279995f34f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00813202-2014-02-28-d5279995f34f`](#source-ctg-observation-nct00813202-2014-02-28-d5279995f34f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00813202-2014-02-28-d5279995f34f`](#source-ctg-observation-nct00813202-2014-02-28-d5279995f34f))

### Sources

<a id="source-ctg-observation-nct00813202-2014-02-28-d5279995f34f"></a>
- **ClinicalTrials.gov record NCT00813202 · retained source version 2014-02-28:d5279995f34fe9552d157b3bd550173e7694ffadf46d39ba149cf8ccdf93324a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00813202) (`ctg-observation-nct00813202-2014-02-28-d5279995f34f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00813202." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00813202-nesiritide-v1 SHA-256: 7bbd049b7981b227cab56ccc5bdcf2ea09138cecfd9329139efa2e814f6948f5.

---

<a id="clinicaltrials-gov-nct00842023-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT00842023

> PeptideScanner retained ClinicalTrials.gov record NCT00842023 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-08-30, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct00842023-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-08-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00842023-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00842023-nesiritide-v1
- Content SHA-256: `c5563dfdec48956ac2f55b4d9327eeb19423698ca925fdb1ad04d8b310f0ac92`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00842023 ([`ctg-observation-nct00842023-2013-08-30-4ce871602280`](#source-ctg-observation-nct00842023-2013-08-30-4ce871602280))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00842023 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-08-30, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00842023-2013-08-30-4ce871602280`](#source-ctg-observation-nct00842023-2013-08-30-4ce871602280))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00842023 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-08-30, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct00842023-2013-08-30-4ce871602280`](#source-ctg-observation-nct00842023-2013-08-30-4ce871602280))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00842023-2013-08-30-4ce871602280`](#source-ctg-observation-nct00842023-2013-08-30-4ce871602280))

### Sources

<a id="source-ctg-observation-nct00842023-2013-08-30-4ce871602280"></a>
- **ClinicalTrials.gov record NCT00842023 · retained source version 2013-08-30:4ce87160228033eb9c4c75e5b9ff334b86a59bdcb35e4628ec18ea0976f9ecd2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00842023) (`ctg-observation-nct00842023-2013-08-30-4ce871602280`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00842023." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct00842023-nesiritide-v1 SHA-256: c5563dfdec48956ac2f55b4d9327eeb19423698ca925fdb1ad04d8b310f0ac92.

---

<a id="clinicaltrials-gov-nct01132846-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT01132846

> PeptideScanner retained ClinicalTrials.gov record NCT01132846 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-08-21, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct01132846-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-08-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01132846-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01132846-nesiritide-v1
- Content SHA-256: `03f0b78e9eb9f7f05e8a4c2cd9085ab6f7714c303a35dde51ebfb27d5ceefc3c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01132846 ([`ctg-observation-nct01132846-2014-08-21-96e6e5dd7920`](#source-ctg-observation-nct01132846-2014-08-21-96e6e5dd7920))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01132846 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-08-21, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01132846-2014-08-21-96e6e5dd7920`](#source-ctg-observation-nct01132846-2014-08-21-96e6e5dd7920))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01132846 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-08-21, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01132846-2014-08-21-96e6e5dd7920`](#source-ctg-observation-nct01132846-2014-08-21-96e6e5dd7920))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01132846-2014-08-21-96e6e5dd7920`](#source-ctg-observation-nct01132846-2014-08-21-96e6e5dd7920))

### Sources

<a id="source-ctg-observation-nct01132846-2014-08-21-96e6e5dd7920"></a>
- **ClinicalTrials.gov record NCT01132846 · retained source version 2014-08-21:96e6e5dd792093b475d0f91d3e02dc0447bfea71006dd707abddd69757af288e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01132846) (`ctg-observation-nct01132846-2014-08-21-96e6e5dd7920`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01132846." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01132846-nesiritide-v1 SHA-256: 03f0b78e9eb9f7f05e8a4c2cd9085ab6f7714c303a35dde51ebfb27d5ceefc3c.

---

<a id="clinicaltrials-gov-nct01413542-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT01413542

> PeptideScanner retained ClinicalTrials.gov record NCT01413542 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-11-04, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct01413542-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-11-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01413542-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01413542-nesiritide-v1
- Content SHA-256: `4317cf4f810fe4ed54cba19e641b8e2cac6fade94464d508e942e74473521632`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01413542 ([`ctg-observation-nct01413542-2015-11-04-d9b9e989d166`](#source-ctg-observation-nct01413542-2015-11-04-d9b9e989d166))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01413542 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-11-04, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01413542-2015-11-04-d9b9e989d166`](#source-ctg-observation-nct01413542-2015-11-04-d9b9e989d166))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01413542 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-11-04, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01413542-2015-11-04-d9b9e989d166`](#source-ctg-observation-nct01413542-2015-11-04-d9b9e989d166))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01413542-2015-11-04-d9b9e989d166`](#source-ctg-observation-nct01413542-2015-11-04-d9b9e989d166))

### Sources

<a id="source-ctg-observation-nct01413542-2015-11-04-d9b9e989d166"></a>
- **ClinicalTrials.gov record NCT01413542 · retained source version 2015-11-04:d9b9e989d166a641333bb5dd5db462547f6e58f1808c07906dceeb6a03e629a1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01413542) (`ctg-observation-nct01413542-2015-11-04-d9b9e989d166`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01413542." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01413542-nesiritide-v1 SHA-256: 4317cf4f810fe4ed54cba19e641b8e2cac6fade94464d508e942e74473521632.

---

<a id="clinicaltrials-gov-nct01440881-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT01440881

> PeptideScanner retained ClinicalTrials.gov record NCT01440881 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-06-06, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct01440881-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-06-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01440881-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01440881-nesiritide-v1
- Content SHA-256: `0c75eac20c92ce0a4ed16b6f6d4afcaa1a715acc05ee234ed9473698c70465f1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01440881 ([`ctg-observation-nct01440881-2014-06-06-be4f743ab581`](#source-ctg-observation-nct01440881-2014-06-06-be4f743ab581))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01440881 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-06-06, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01440881-2014-06-06-be4f743ab581`](#source-ctg-observation-nct01440881-2014-06-06-be4f743ab581))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01440881 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-06-06, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01440881-2014-06-06-be4f743ab581`](#source-ctg-observation-nct01440881-2014-06-06-be4f743ab581))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01440881-2014-06-06-be4f743ab581`](#source-ctg-observation-nct01440881-2014-06-06-be4f743ab581))

### Sources

<a id="source-ctg-observation-nct01440881-2014-06-06-be4f743ab581"></a>
- **ClinicalTrials.gov record NCT01440881 · retained source version 2014-06-06:be4f743ab581c61a01793c1cf9bc59d70788f76edf885d9f085efd36c690b313** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01440881) (`ctg-observation-nct01440881-2014-06-06-be4f743ab581`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01440881." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01440881-nesiritide-v1 SHA-256: 0c75eac20c92ce0a4ed16b6f6d4afcaa1a715acc05ee234ed9473698c70465f1.

---

<a id="clinicaltrials-gov-nct01544998-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT01544998

> PeptideScanner retained ClinicalTrials.gov record NCT01544998 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-03-22, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct01544998-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-03-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01544998-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01544998-nesiritide-v1
- Content SHA-256: `cfc9e81c85c84fdc649fea19f3a17929bc3973089844e9478a348548b1ac61c6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01544998 ([`ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25`](#source-ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01544998 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-03-22, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25`](#source-ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01544998 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-03-22, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25`](#source-ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25`](#source-ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25))

### Sources

<a id="source-ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25"></a>
- **ClinicalTrials.gov record NCT01544998 · retained source version 2018-03-22:bbaf6eb30d25f0392d575a8c0ea0e98fde4526f7efaf21727bd998ce4136343c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01544998) (`ctg-observation-nct01544998-2018-03-22-bbaf6eb30d25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01544998." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01544998-nesiritide-v1 SHA-256: cfc9e81c85c84fdc649fea19f3a17929bc3973089844e9478a348548b1ac61c6.

---

<a id="clinicaltrials-gov-nct01977859-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT01977859

> PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct01977859-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-02-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01977859-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01977859-nesiritide-v1
- Content SHA-256: `aba0864d3b70ec467ea70a2bdef955657e8383885aa570db23e7da5e79acf670`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01977859 ([`ctg-observation-nct01977859-2018-02-14-3cdea9726f6c`](#source-ctg-observation-nct01977859-2018-02-14-3cdea9726f6c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01977859-2018-02-14-3cdea9726f6c`](#source-ctg-observation-nct01977859-2018-02-14-3cdea9726f6c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct01977859-2018-02-14-3cdea9726f6c`](#source-ctg-observation-nct01977859-2018-02-14-3cdea9726f6c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01977859-2018-02-14-3cdea9726f6c`](#source-ctg-observation-nct01977859-2018-02-14-3cdea9726f6c))

### Sources

<a id="source-ctg-observation-nct01977859-2018-02-14-3cdea9726f6c"></a>
- **ClinicalTrials.gov record NCT01977859 · retained source version 2018-02-14:3cdea9726f6ccdc904c99375e96e3ddfd6f305113f7db1f9886323d8de64ea54** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01977859) (`ctg-observation-nct01977859-2018-02-14-3cdea9726f6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01977859." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct01977859-nesiritide-v1 SHA-256: aba0864d3b70ec467ea70a2bdef955657e8383885aa570db23e7da5e79acf670.

---

<a id="clinicaltrials-gov-nct02608996-nesiritide-v1"></a>

## ClinicalTrials.gov record NCT02608996

> PeptideScanner retained ClinicalTrials.gov record NCT02608996 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-01-03, and PeptideScanner's reviewed identity mapping was nesiritide.

- Evidence object: `story:clinicaltrials-gov-nct02608996-nesiritide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-01-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02608996-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct02608996-nesiritide-v1
- Content SHA-256: `6d5296c3b8fe5b85fb4d49c828cf40a846d365463605ec32fe230af7bfaa2f9b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02608996 ([`ctg-observation-nct02608996-2018-01-03-ff4f58d22781`](#source-ctg-observation-nct02608996-2018-01-03-ff4f58d22781))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02608996 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-01-03, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct02608996-2018-01-03-ff4f58d22781`](#source-ctg-observation-nct02608996-2018-01-03-ff4f58d22781))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02608996 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-01-03, and PeptideScanner's reviewed identity mapping was nesiritide. ([`ctg-observation-nct02608996-2018-01-03-ff4f58d22781`](#source-ctg-observation-nct02608996-2018-01-03-ff4f58d22781))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02608996-2018-01-03-ff4f58d22781`](#source-ctg-observation-nct02608996-2018-01-03-ff4f58d22781))

### Sources

<a id="source-ctg-observation-nct02608996-2018-01-03-ff4f58d22781"></a>
- **ClinicalTrials.gov record NCT02608996 · retained source version 2018-01-03:ff4f58d22781d1415a7f0bc56761b9013bbbe6419303ae9421b4eb33507954aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02608996) (`ctg-observation-nct02608996-2018-01-03-ff4f58d22781`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02608996." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#clinicaltrials-gov-nct02608996-nesiritide-v1 SHA-256: 6d5296c3b8fe5b85fb4d49c828cf40a846d365463605ec32fe230af7bfaa2f9b.

---

<a id="fda-drugs-nda020920-v1"></a>

## Drugs@FDA application NDA020920

> The official Drugs@FDA dataset lists original submission 1 for NDA 020920 with status AP dated 2001-08-10, and names nesiritide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda020920:v1`
- Evidence domain: Regulatory
- Date in source: 2001-08-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda020920/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#fda-drugs-nda020920-v1
- Content SHA-256: `ec7f2a0c0b06466498f244b55ba7374f22dd19f8c2667ba62ae65badd8a5e343`

### Claims and source pins

#### Headline

Drugs@FDA application NDA020920 ([`fda-drugs-nda020920-2001-08-10-129c4de588ed`](#source-fda-drugs-nda020920-2001-08-10-129c4de588ed))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 020920 with status AP dated 2001-08-10, and names nesiritide among the application record's active ingredients. ([`fda-drugs-nda020920-2001-08-10-129c4de588ed`](#source-fda-drugs-nda020920-2001-08-10-129c4de588ed))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 020920 with status AP dated 2001-08-10, and names nesiritide among the application record's active ingredients. ([`fda-drugs-nda020920-2001-08-10-129c4de588ed`](#source-fda-drugs-nda020920-2001-08-10-129c4de588ed))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda020920-2001-08-10-129c4de588ed`](#source-fda-drugs-nda020920-2001-08-10-129c4de588ed))

### Sources

<a id="source-fda-drugs-nda020920-2001-08-10-129c4de588ed"></a>
- **Drugs@FDA application NDA020920 · original submission status AP · 2001-08-10 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA020920%22&limit=1) (`fda-drugs-nda020920-2001-08-10-129c4de588ed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA020920." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#fda-drugs-nda020920-v1 SHA-256: ec7f2a0c0b06466498f244b55ba7374f22dd19f8c2667ba62ae65badd8a5e343.

---

<a id="federal-register-01-10450-v1"></a>

## Federal Register notice 01-10450

> The Federal Register published notice 01-10450, attributed to FDA and its parent HHS department, on 2001-04-27. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

- Evidence object: `story:federal-register-01-10450:v1`
- Evidence domain: Regulatory
- Date in source: 2001-04-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-01-10450/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-01-10450-v1
- Content SHA-256: `4f31db5a784b944c7fc0e6621d8ac1c5a088c4ac97d61cb69d68d4adaf7d8525`

### Claims and source pins

#### Headline

Federal Register notice 01-10450 ([`federal-register-01-10450-bc8082a3f599`](#source-federal-register-01-10450-bc8082a3f599))

#### Summary

The Federal Register published notice 01-10450, attributed to FDA and its parent HHS department, on 2001-04-27. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-01-10450-bc8082a3f599`](#source-federal-register-01-10450-bc8082a3f599))

#### Paragraph 1

The Federal Register published notice 01-10450, attributed to FDA and its parent HHS department, on 2001-04-27. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-01-10450-bc8082a3f599`](#source-federal-register-01-10450-bc8082a3f599))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-01-10450-bc8082a3f599`](#source-federal-register-01-10450-bc8082a3f599))

### Sources

<a id="source-federal-register-01-10450-bc8082a3f599"></a>
- **Federal Register notice 01-10450 · published 2001-04-27 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2001-04-27/pdf/01-10450.pdf) (`federal-register-01-10450-bc8082a3f599`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 01-10450." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-01-10450-v1 SHA-256: 4f31db5a784b944c7fc0e6621d8ac1c5a088c4ac97d61cb69d68d4adaf7d8525.

---

<a id="federal-register-2020-10367-v1"></a>

## Federal Register notice 2020-10367

> The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

- Evidence object: `story:federal-register-2020-10367:v1`
- Evidence domain: Regulatory
- Date in source: 2020-05-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2020-10367/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-2020-10367-v1
- Content SHA-256: `436818b035db6509ae72a32dd0f50ae3068d3223cbb4b1fc16877f713feb2b0b`

### Claims and source pins

#### Headline

Federal Register notice 2020-10367 ([`federal-register-2020-10367-cba016da5975`](#source-federal-register-2020-10367-cba016da5975))

#### Summary

The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-2020-10367-cba016da5975`](#source-federal-register-2020-10367-cba016da5975))

#### Paragraph 1

The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-2020-10367-cba016da5975`](#source-federal-register-2020-10367-cba016da5975))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2020-10367-cba016da5975`](#source-federal-register-2020-10367-cba016da5975))

### Sources

<a id="source-federal-register-2020-10367-cba016da5975"></a>
- **Federal Register notice 2020-10367 · published 2020-05-14 · Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2020-05-14/pdf/2020-10367.pdf) (`federal-register-2020-10367-cba016da5975`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2020-10367." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-2020-10367-v1 SHA-256: 436818b035db6509ae72a32dd0f50ae3068d3223cbb4b1fc16877f713feb2b0b.

---

<a id="federal-register-2021-00118-v1"></a>

## Federal Register notice 2021-00118

> The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

- Evidence object: `story:federal-register-2021-00118:v1`
- Evidence domain: Regulatory
- Date in source: 2021-01-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2021-00118/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-2021-00118-v1
- Content SHA-256: `5157c1c2cd6ceef5be6df6cc6db80a34718b67eac1c2d5de0a02d6ec9716512b`

### Claims and source pins

#### Headline

Federal Register notice 2021-00118 ([`federal-register-2021-00118-d4e4a47757bf`](#source-federal-register-2021-00118-d4e4a47757bf))

#### Summary

The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-2021-00118-d4e4a47757bf`](#source-federal-register-2021-00118-d4e4a47757bf))

#### Paragraph 1

The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-2021-00118-d4e4a47757bf`](#source-federal-register-2021-00118-d4e4a47757bf))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2021-00118-d4e4a47757bf`](#source-federal-register-2021-00118-d4e4a47757bf))

### Sources

<a id="source-federal-register-2021-00118-d4e4a47757bf"></a>
- **Federal Register notice 2021-00118 · published 2021-01-08 · Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2021-01-08/pdf/2021-00118.pdf) (`federal-register-2021-00118-d4e4a47757bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2021-00118." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-2021-00118-v1 SHA-256: 5157c1c2cd6ceef5be6df6cc6db80a34718b67eac1c2d5de0a02d6ec9716512b.

---

<a id="federal-register-98-33915-v1"></a>

## Federal Register notice 98-33915

> The Federal Register published notice 98-33915, attributed to FDA and its parent HHS department, on 1998-12-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

- Evidence object: `story:federal-register-98-33915:v1`
- Evidence domain: Regulatory
- Date in source: 1998-12-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-98-33915/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-98-33915-v1
- Content SHA-256: `9e97535acf0e9a33fbf7a2f7d2894f8c199a5fe8534c9d48c3a436a764994948`

### Claims and source pins

#### Headline

Federal Register notice 98-33915 ([`federal-register-98-33915-dd470136b359`](#source-federal-register-98-33915-dd470136b359))

#### Summary

The Federal Register published notice 98-33915, attributed to FDA and its parent HHS department, on 1998-12-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-98-33915-dd470136b359`](#source-federal-register-98-33915-dd470136b359))

#### Paragraph 1

The Federal Register published notice 98-33915, attributed to FDA and its parent HHS department, on 1998-12-23. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-98-33915-dd470136b359`](#source-federal-register-98-33915-dd470136b359))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-98-33915-dd470136b359`](#source-federal-register-98-33915-dd470136b359))

### Sources

<a id="source-federal-register-98-33915-dd470136b359"></a>
- **Federal Register notice 98-33915 · published 1998-12-23 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-1998-12-23/pdf/98-33915.pdf) (`federal-register-98-33915-dd470136b359`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 98-33915." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-98-33915-v1 SHA-256: 9e97535acf0e9a33fbf7a2f7d2894f8c199a5fe8534c9d48c3a436a764994948.

---

<a id="federal-register-e6-16091-v1"></a>

## Federal Register notice E6-16091

> The Federal Register published notice E6-16091, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

- Evidence object: `story:federal-register-e6-16091:v1`
- Evidence domain: Regulatory
- Date in source: 2006-10-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-e6-16091/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-e6-16091-v1
- Content SHA-256: `f07b7abe10c38549297a6ec6b50d8a624ebc489ce3cf6f42b8c5ccef0cec0a68`

### Claims and source pins

#### Headline

Federal Register notice E6-16091 ([`federal-register-e6-16091-77f8ccb6e171`](#source-federal-register-e6-16091-77f8ccb6e171))

#### Summary

The Federal Register published notice E6-16091, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-e6-16091-77f8ccb6e171`](#source-federal-register-e6-16091-77f8ccb6e171))

#### Paragraph 1

The Federal Register published notice E6-16091, attributed to FDA and its parent HHS department, on 2006-10-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide. ([`federal-register-e6-16091-77f8ccb6e171`](#source-federal-register-e6-16091-77f8ccb6e171))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-e6-16091-77f8ccb6e171`](#source-federal-register-e6-16091-77f8ccb6e171))

### Sources

<a id="source-federal-register-e6-16091-77f8ccb6e171"></a>
- **Federal Register notice E6-16091 · published 2006-10-02 · Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16091.pdf) (`federal-register-e6-16091-77f8ccb6e171`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice E6-16091." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#federal-register-e6-16091-v1 SHA-256: f07b7abe10c38549297a6ec6b50d8a624ebc489ce3cf6f42b8c5ccef0cec0a68.

---

<a id="pubmed-pmid-15102572-nesiritide-v1"></a>

## Nesiritide for the treatment of congestive heart failure.

> PubMed lists PMID 15102572 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15102572-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15102572-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15102572-nesiritide-v1
- Content SHA-256: `618a10fe10384aa30b4ea0d0fd8e5af04e10a440513aa8d65b720779c46c6f6a`

### Claims and source pins

#### Headline

Nesiritide for the treatment of congestive heart failure. ([`pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055`](#source-pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055))

#### Summary

PubMed lists PMID 15102572 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055`](#source-pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055))

#### Paragraph 1

PubMed lists PMID 15102572 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055`](#source-pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055`](#source-pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055))

### Sources

<a id="source-pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055"></a>
- **Nesiritide for the treatment of congestive heart failure. · retained source version 1:2019-09-17:current:baf0ea20a05561470185705154ee538a96dddc8c5c41a4036bc22ef4d2ca937f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15102572/) (`pubmed-observation-pmid-15102572-2019-09-17-baf0ea20a055`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide for the treatment of congestive heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15102572-nesiritide-v1 SHA-256: 618a10fe10384aa30b4ea0d0fd8e5af04e10a440513aa8d65b720779c46c6f6a.

---

<a id="pubmed-pmid-15154998-nesiritide-v1"></a>

## Is there a use for nesiritide in pediatric patients?

> PubMed lists PMID 15154998 in Journal of intensive care medicine as Editorial, Review, with publication-date metadata of 2004 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15154998-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15154998-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15154998-nesiritide-v1
- Content SHA-256: `275d0bb11d7e15d4f42d5c483d85cd282f1bab278c78fa65d67a6f16428ac1c0`

### Claims and source pins

#### Headline

Is there a use for nesiritide in pediatric patients? ([`pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8`](#source-pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8))

#### Summary

PubMed lists PMID 15154998 in Journal of intensive care medicine as Editorial, Review, with publication-date metadata of 2004 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8`](#source-pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8))

#### Paragraph 1

PubMed lists PMID 15154998 in Journal of intensive care medicine as Editorial, Review, with publication-date metadata of 2004 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8`](#source-pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8`](#source-pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8))

### Sources

<a id="source-pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8"></a>
- **Is there a use for nesiritide in pediatric patients? · retained source version 1:2007-11-15:current:e7c915b514b8e0cb49369ab6666a94f44502b2aa780c09db2e25c858314ace7a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15154998/) (`pubmed-observation-pmid-15154998-2007-11-15-e7c915b514b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Is there a use for nesiritide in pediatric patients?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15154998-nesiritide-v1 SHA-256: 275d0bb11d7e15d4f42d5c483d85cd282f1bab278c78fa65d67a6f16428ac1c0.

---

<a id="pubmed-pmid-15470300-nesiritide-v1"></a>

## Decompensated heart failure: is there a role for the outpatient use of nesiritide?

> PubMed lists PMID 15470300 in Congestive heart failure (Greenwich, Conn.) as Journal Article, Review, with publication-date metadata of 2004 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15470300-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15470300-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15470300-nesiritide-v1
- Content SHA-256: `3662b93a3cd243ff08ab671894c1dfc401b91d6a4181e767b46fa5c47bad916b`

### Claims and source pins

#### Headline

Decompensated heart failure: is there a role for the outpatient use of nesiritide? ([`pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a`](#source-pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a))

#### Summary

PubMed lists PMID 15470300 in Congestive heart failure (Greenwich, Conn.) as Journal Article, Review, with publication-date metadata of 2004 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a`](#source-pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a))

#### Paragraph 1

PubMed lists PMID 15470300 in Congestive heart failure (Greenwich, Conn.) as Journal Article, Review, with publication-date metadata of 2004 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a`](#source-pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a`](#source-pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a))

### Sources

<a id="source-pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a"></a>
- **Decompensated heart failure: is there a role for the outpatient use of nesiritide? · retained source version 1:2019-11-09:current:dfe819d0657a1224d0122b02e4b00db4e89944f6408b849b78594c50883042b3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15470300/) (`pubmed-observation-pmid-15470300-2019-11-09-dfe819d0657a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Decompensated heart failure: is there a role for the outpatient use of nesiritide?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15470300-nesiritide-v1 SHA-256: 3662b93a3cd243ff08ab671894c1dfc401b91d6a4181e767b46fa5c47bad916b.

---

<a id="pubmed-pmid-15500426-nesiritide-v1"></a>

## Nesiritide for the treatment of decompensated heart failure.

> PubMed lists PMID 15500426 in Expert review of cardiovascular therapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15500426-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15500426-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15500426-nesiritide-v1
- Content SHA-256: `c86de7fea2a99b1f17838327d837998821a015792cbc7681d64a8e8ff63415d5`

### Claims and source pins

#### Headline

Nesiritide for the treatment of decompensated heart failure. ([`pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993`](#source-pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993))

#### Summary

PubMed lists PMID 15500426 in Expert review of cardiovascular therapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993`](#source-pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993))

#### Paragraph 1

PubMed lists PMID 15500426 in Expert review of cardiovascular therapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993`](#source-pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993`](#source-pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993))

### Sources

<a id="source-pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993"></a>
- **Nesiritide for the treatment of decompensated heart failure. · retained source version 1:2007-11-15:current:3710a4dce99307df226be92cec8dd0b46addb1dd3a4f1a1dd517c42f00dd86c9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15500426/) (`pubmed-observation-pmid-15500426-2007-11-15-3710a4dce993`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide for the treatment of decompensated heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15500426-nesiritide-v1 SHA-256: c86de7fea2a99b1f17838327d837998821a015792cbc7681d64a8e8ff63415d5.

---

<a id="pubmed-pmid-15605677-nesiritide-v1"></a>

## The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.

> PubMed lists PMID 15605677 in International journal of clinical practice as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15605677-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15605677-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15605677-nesiritide-v1
- Content SHA-256: `46617f8e9706ef4441a4474e6d5dd0d6782fb595824f7990e8dfccf9ecbb7676`

### Claims and source pins

#### Headline

The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure. ([`pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc`](#source-pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc))

#### Summary

PubMed lists PMID 15605677 in International journal of clinical practice as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc`](#source-pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc))

#### Paragraph 1

PubMed lists PMID 15605677 in International journal of clinical practice as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc`](#source-pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc`](#source-pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc))

### Sources

<a id="source-pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc"></a>
- **The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure. · retained source version 1:2019-11-09:current:5bb3ad41d1cc2a619ffbaf1c9c3e707ff266986195b38c63469af1204a36c5ac** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15605677/) (`pubmed-observation-pmid-15605677-2019-11-09-5bb3ad41d1cc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15605677-nesiritide-v1 SHA-256: 46617f8e9706ef4441a4474e6d5dd0d6782fb595824f7990e8dfccf9ecbb7676.

---

<a id="pubmed-pmid-15700894-nesiritide-v1"></a>

## Intermittent nesiritide therapy in outpatients with chronic heart failure.

> PubMed lists PMID 15700894 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2005-01-15 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-15700894-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-02-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-15700894-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15700894-nesiritide-v1
- Content SHA-256: `615ebc77c963d1cb269bac0cc86bc2c436512d2e6f16fe45582377f0526d9cf1`

### Claims and source pins

#### Headline

Intermittent nesiritide therapy in outpatients with chronic heart failure. ([`pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8`](#source-pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8))

#### Summary

PubMed lists PMID 15700894 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2005-01-15 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8`](#source-pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8))

#### Paragraph 1

PubMed lists PMID 15700894 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Clinical Trial, Comparative Study, Journal Article, with publication-date metadata of 2005-01-15 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8`](#source-pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8`](#source-pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8))

### Sources

<a id="source-pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8"></a>
- **Intermittent nesiritide therapy in outpatients with chronic heart failure. · retained source version 1:2019-02-22:current:b967a1fd42f8b701b4bdd08fb765b86f03a89dfd546d8d73e592ad6f132b190b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/15700894/) (`pubmed-observation-pmid-15700894-2019-02-22-b967a1fd42f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Intermittent nesiritide therapy in outpatients with chronic heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-15700894-nesiritide-v1 SHA-256: 615ebc77c963d1cb269bac0cc86bc2c436512d2e6f16fe45582377f0526d9cf1.

---

<a id="pubmed-pmid-16183453-nesiritide-v1"></a>

## Critical review and recommendations for nesiritide use in the emergency department.

> PubMed lists PMID 16183453 in The Journal of emergency medicine as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16183453-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16183453-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16183453-nesiritide-v1
- Content SHA-256: `255e955c12973bfa879535ee93f3371a5c79f83759d9d4345f197a3d53018729`

### Claims and source pins

#### Headline

Critical review and recommendations for nesiritide use in the emergency department. ([`pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c`](#source-pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c))

#### Summary

PubMed lists PMID 16183453 in The Journal of emergency medicine as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c`](#source-pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c))

#### Paragraph 1

PubMed lists PMID 16183453 in The Journal of emergency medicine as Journal Article, Review, with publication-date metadata of 2005-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c`](#source-pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c`](#source-pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c))

### Sources

<a id="source-pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c"></a>
- **Critical review and recommendations for nesiritide use in the emergency department. · retained source version 1:2013-11-21:current:bcd65f06569cb91e4ac4c67eaf34db87e40993dfed90d138221c3d389bf7c480** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16183453/) (`pubmed-observation-pmid-16183453-2013-11-21-bcd65f06569c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Critical review and recommendations for nesiritide use in the emergency department." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16183453-nesiritide-v1 SHA-256: 255e955c12973bfa879535ee93f3371a5c79f83759d9d4345f197a3d53018729.

---

<a id="pubmed-pmid-16333235-nesiritide-v1"></a>

## Nesiritide: past, present, and future.

> PubMed lists PMID 16333235 in Minerva cardioangiologica as Comparative Study, Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16333235-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16333235-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16333235-nesiritide-v1
- Content SHA-256: `64981529301985f812f795aab488200e9b4029c3dc501ab045a13703b6f92aff`

### Claims and source pins

#### Headline

Nesiritide: past, present, and future. ([`pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a`](#source-pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a))

#### Summary

PubMed lists PMID 16333235 in Minerva cardioangiologica as Comparative Study, Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a`](#source-pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a))

#### Paragraph 1

PubMed lists PMID 16333235 in Minerva cardioangiologica as Comparative Study, Journal Article, Review, with publication-date metadata of 2005-12 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a`](#source-pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a`](#source-pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a))

### Sources

<a id="source-pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a"></a>
- **Nesiritide: past, present, and future. · retained source version 1:2007-11-15:current:42af16707c2ac2ad0c1af04854cd9d7050c45a031729fca3544909dc9e770012** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16333235/) (`pubmed-observation-pmid-16333235-2007-11-15-42af16707c2a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide: past, present, and future." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16333235-nesiritide-v1 SHA-256: 64981529301985f812f795aab488200e9b4029c3dc501ab045a13703b6f92aff.

---

<a id="pubmed-pmid-16443809-nesiritide-v1"></a>

## Nesiritide: the latest drug for treating heart failure.

> PubMed lists PMID 16443809 in Critical care nurse as Case Reports, Journal Article, Review, with publication-date metadata of 2006-02 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16443809-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16443809-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16443809-nesiritide-v1
- Content SHA-256: `d4b94aa7a42406c308580698f8f646bfa94cfdf54daea7e78da309929a2c21e9`

### Claims and source pins

#### Headline

Nesiritide: the latest drug for treating heart failure. ([`pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166`](#source-pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166))

#### Summary

PubMed lists PMID 16443809 in Critical care nurse as Case Reports, Journal Article, Review, with publication-date metadata of 2006-02 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166`](#source-pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166))

#### Paragraph 1

PubMed lists PMID 16443809 in Critical care nurse as Case Reports, Journal Article, Review, with publication-date metadata of 2006-02 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166`](#source-pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166`](#source-pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166))

### Sources

<a id="source-pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166"></a>
- **Nesiritide: the latest drug for treating heart failure. · retained source version 1:2007-11-15:current:ab27dbd651665c825aeba5cfaa8682ee8be09e5a48212d0fde3bc6eef62ffeb1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16443809/) (`pubmed-observation-pmid-16443809-2007-11-15-ab27dbd65166`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide: the latest drug for treating heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16443809-nesiritide-v1 SHA-256: d4b94aa7a42406c308580698f8f646bfa94cfdf54daea7e78da309929a2c21e9.

---

<a id="pubmed-pmid-16503047-nesiritide-v1"></a>

## \[Nesiritide in heart failure: commercial success or therapeutic advance?\].

> PubMed lists PMID 16503047 in Revue medicale suisse as English Abstract, Journal Article, Review, with publication-date metadata of 2006-01-25 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16503047-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16503047-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16503047-nesiritide-v1
- Content SHA-256: `d472980b284fc12fce2b93d9d92caa220c772c09e1c5f0ff2bdd4f2a8f0eb01a`

### Claims and source pins

#### Headline

\[Nesiritide in heart failure: commercial success or therapeutic advance?\]. ([`pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e`](#source-pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e))

#### Summary

PubMed lists PMID 16503047 in Revue medicale suisse as English Abstract, Journal Article, Review, with publication-date metadata of 2006-01-25 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e`](#source-pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e))

#### Paragraph 1

PubMed lists PMID 16503047 in Revue medicale suisse as English Abstract, Journal Article, Review, with publication-date metadata of 2006-01-25 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e`](#source-pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e`](#source-pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e))

### Sources

<a id="source-pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e"></a>
- **\[Nesiritide in heart failure: commercial success or therapeutic advance?\]. · retained source version 1:2007-11-15:current:50d49c15ce3e93d74ad767e32fd3563f49a500d28d282431b92ec779b3b8f088** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16503047/) (`pubmed-observation-pmid-16503047-2007-11-15-50d49c15ce3e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Nesiritide in heart failure: commercial success or therapeutic advance?\]." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16503047-nesiritide-v1 SHA-256: d472980b284fc12fce2b93d9d92caa220c772c09e1c5f0ff2bdd4f2a8f0eb01a.

---

<a id="pubmed-pmid-16509026-nesiritide-v1"></a>

## Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.

> PubMed lists PMID 16509026 in Pharmacotherapy as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16509026-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16509026-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16509026-nesiritide-v1
- Content SHA-256: `fc2b4d83508108c8ecf9da3355b9c26637d17493e7858040e487b32883d6abd9`

### Claims and source pins

#### Headline

Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. ([`pubmed-observation-pmid-16509026-2019-09-17-427eab852e05`](#source-pubmed-observation-pmid-16509026-2019-09-17-427eab852e05))

#### Summary

PubMed lists PMID 16509026 in Pharmacotherapy as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16509026-2019-09-17-427eab852e05`](#source-pubmed-observation-pmid-16509026-2019-09-17-427eab852e05))

#### Paragraph 1

PubMed lists PMID 16509026 in Pharmacotherapy as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16509026-2019-09-17-427eab852e05`](#source-pubmed-observation-pmid-16509026-2019-09-17-427eab852e05))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16509026-2019-09-17-427eab852e05`](#source-pubmed-observation-pmid-16509026-2019-09-17-427eab852e05))

### Sources

<a id="source-pubmed-observation-pmid-16509026-2019-09-17-427eab852e05"></a>
- **Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. · retained source version 1:2019-09-17:current:427eab852e05829937520f836f7c1b4c5e8a799b5d8c0c245def63b7cd4257e7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16509026/) (`pubmed-observation-pmid-16509026-2019-09-17-427eab852e05`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16509026-nesiritide-v1 SHA-256: fc2b4d83508108c8ecf9da3355b9c26637d17493e7858040e487b32883d6abd9.

---

<a id="pubmed-pmid-16999657-nesiritide-v1"></a>

## Nesiritide: harmful or harmless?

> PubMed lists PMID 16999657 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16999657-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2007-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16999657-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16999657-nesiritide-v1
- Content SHA-256: `bc9f663dc0198324f32a8d4ecdb62a7d923eb898d7d9b424281c327c7d144b24`

### Claims and source pins

#### Headline

Nesiritide: harmful or harmless? ([`pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce`](#source-pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce))

#### Summary

PubMed lists PMID 16999657 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce`](#source-pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce))

#### Paragraph 1

PubMed lists PMID 16999657 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce`](#source-pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce`](#source-pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce))

### Sources

<a id="source-pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce"></a>
- **Nesiritide: harmful or harmless? · retained source version 1:2007-11-15:current:25945ae375cee4bdf69c56e436b1170e038df1a666ec0c1eb051a002cfcce5e9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16999657/) (`pubmed-observation-pmid-16999657-2007-11-15-25945ae375ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide: harmful or harmless?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-16999657-nesiritide-v1 SHA-256: bc9f663dc0198324f32a8d4ecdb62a7d923eb898d7d9b424281c327c7d144b24.

---

<a id="pubmed-pmid-17056828-nesiritide-v1"></a>

## Nesiritide: trials and tribulations.

> PubMed lists PMID 17056828 in Journal of cardiovascular pharmacology and therapeutics as Journal Article, Review, with publication-date metadata of 2006-09 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17056828-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17056828-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17056828-nesiritide-v1
- Content SHA-256: `e50db1a544c3ff36f742fc2bedf41e1ee59abce235d8a69f2e40f1d063566f8a`

### Claims and source pins

#### Headline

Nesiritide: trials and tribulations. ([`pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06`](#source-pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06))

#### Summary

PubMed lists PMID 17056828 in Journal of cardiovascular pharmacology and therapeutics as Journal Article, Review, with publication-date metadata of 2006-09 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06`](#source-pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06))

#### Paragraph 1

PubMed lists PMID 17056828 in Journal of cardiovascular pharmacology and therapeutics as Journal Article, Review, with publication-date metadata of 2006-09 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06`](#source-pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06`](#source-pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06))

### Sources

<a id="source-pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06"></a>
- **Nesiritide: trials and tribulations. · retained source version 1:2013-11-21:current:4026ecaafb064f7d89d907e39fd98159f3034e1298bb463fde165e898335eb53** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17056828/) (`pubmed-observation-pmid-17056828-2013-11-21-4026ecaafb06`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide: trials and tribulations." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17056828-nesiritide-v1 SHA-256: e50db1a544c3ff36f742fc2bedf41e1ee59abce235d8a69f2e40f1d063566f8a.

---

<a id="pubmed-pmid-17192168-nesiritide-v1"></a>

## Practical application of nonrandomized research to patient care: a case study of nesiritide.

> PubMed lists PMID 17192168 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17192168-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17192168-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17192168-nesiritide-v1
- Content SHA-256: `de9d22dd199422fa0612169616836482c14c6787504bc9c0efff61f7f3cd9314`

### Claims and source pins

#### Headline

Practical application of nonrandomized research to patient care: a case study of nesiritide. ([`pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d`](#source-pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d))

#### Summary

PubMed lists PMID 17192168 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d`](#source-pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d))

#### Paragraph 1

PubMed lists PMID 17192168 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d`](#source-pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d`](#source-pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d))

### Sources

<a id="source-pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d"></a>
- **Practical application of nonrandomized research to patient care: a case study of nesiritide. · retained source version 1:2019-12-10:current:9d35076dbe3d4779a2dc2172f659b3faeb175ab8eb7373ae7cce2aa110237318** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17192168/) (`pubmed-observation-pmid-17192168-2019-12-10-9d35076dbe3d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Practical application of nonrandomized research to patient care: a case study of nesiritide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17192168-nesiritide-v1 SHA-256: de9d22dd199422fa0612169616836482c14c6787504bc9c0efff61f7f3cd9314.

---

<a id="pubmed-pmid-17327288-nesiritide-v1"></a>

## Nesiritide compared with milrinone for cardiac surgery.

> PubMed lists PMID 17327288 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2007-02-27 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17327288-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17327288-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17327288-nesiritide-v1
- Content SHA-256: `84be06c67491deafa3a6eef4571a7f95a8c8f7ca7fcc5c8c4c537b6ebac0f579`

### Claims and source pins

#### Headline

Nesiritide compared with milrinone for cardiac surgery. ([`pubmed-observation-pmid-17327288-2013-11-21-2ed683263868`](#source-pubmed-observation-pmid-17327288-2013-11-21-2ed683263868))

#### Summary

PubMed lists PMID 17327288 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2007-02-27 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17327288-2013-11-21-2ed683263868`](#source-pubmed-observation-pmid-17327288-2013-11-21-2ed683263868))

#### Paragraph 1

PubMed lists PMID 17327288 in The Annals of pharmacotherapy as Comparative Study, Journal Article, Review, with publication-date metadata of 2007-02-27 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17327288-2013-11-21-2ed683263868`](#source-pubmed-observation-pmid-17327288-2013-11-21-2ed683263868))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17327288-2013-11-21-2ed683263868`](#source-pubmed-observation-pmid-17327288-2013-11-21-2ed683263868))

### Sources

<a id="source-pubmed-observation-pmid-17327288-2013-11-21-2ed683263868"></a>
- **Nesiritide compared with milrinone for cardiac surgery. · retained source version 1:2013-11-21:current:2ed683263868e32ca0a891ae284ccb7f8da8311d8ab207c0996c2ac30e3869b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17327288/) (`pubmed-observation-pmid-17327288-2013-11-21-2ed683263868`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide compared with milrinone for cardiac surgery." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17327288-nesiritide-v1 SHA-256: 84be06c67491deafa3a6eef4571a7f95a8c8f7ca7fcc5c8c4c537b6ebac0f579.

---

<a id="pubmed-pmid-17461695-nesiritide-v1"></a>

## Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.

> PubMed lists PMID 17461695 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17461695-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-12-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17461695-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17461695-nesiritide-v1
- Content SHA-256: `8890ab663c1cd8202a76a9d14c4eec7786686b8dd48f0729980637ce5bbf8cbf`

### Claims and source pins

#### Headline

Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. ([`pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b`](#source-pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b))

#### Summary

PubMed lists PMID 17461695 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b`](#source-pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b))

#### Paragraph 1

PubMed lists PMID 17461695 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b`](#source-pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b`](#source-pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b))

### Sources

<a id="source-pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b"></a>
- **Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. · retained source version 1:2019-12-10:current:035a6a76771bd978f6ad1dd96d2a4dc70af4a99582f96bdcd43696dc9fdff8a4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17461695/) (`pubmed-observation-pmid-17461695-2019-12-10-035a6a76771b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17461695-nesiritide-v1 SHA-256: 8890ab663c1cd8202a76a9d14c4eec7786686b8dd48f0729980637ce5bbf8cbf.

---

<a id="pubmed-pmid-17461696-nesiritide-v1"></a>

## Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.

> PubMed lists PMID 17461696 in Pharmacotherapy as Comment, Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17461696-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2010-11-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17461696-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17461696-nesiritide-v1
- Content SHA-256: `f6baf7612e5cdb82fbb0b7f065b0e6b9b2bd20c49a13c629da24010d0ad3aaa0`

### Claims and source pins

#### Headline

Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide. ([`pubmed-observation-pmid-17461696-2010-11-18-83439f476d31`](#source-pubmed-observation-pmid-17461696-2010-11-18-83439f476d31))

#### Summary

PubMed lists PMID 17461696 in Pharmacotherapy as Comment, Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17461696-2010-11-18-83439f476d31`](#source-pubmed-observation-pmid-17461696-2010-11-18-83439f476d31))

#### Paragraph 1

PubMed lists PMID 17461696 in Pharmacotherapy as Comment, Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17461696-2010-11-18-83439f476d31`](#source-pubmed-observation-pmid-17461696-2010-11-18-83439f476d31))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17461696-2010-11-18-83439f476d31`](#source-pubmed-observation-pmid-17461696-2010-11-18-83439f476d31))

### Sources

<a id="source-pubmed-observation-pmid-17461696-2010-11-18-83439f476d31"></a>
- **Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide. · retained source version 1:2010-11-18:current:83439f476d31a43f7253dd64ea6ab5b77a13ad6dc57b370f85d217419faed378** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17461696/) (`pubmed-observation-pmid-17461696-2010-11-18-83439f476d31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-17461696-nesiritide-v1 SHA-256: f6baf7612e5cdb82fbb0b7f065b0e6b9b2bd20c49a13c629da24010d0ad3aaa0.

---

<a id="pubmed-pmid-18629384-nesiritide-v1"></a>

## Nesiritide: the clinical experience.

> PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18629384-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18629384-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18629384-nesiritide-v1
- Content SHA-256: `9b657e716776beeb08fff90d97ae1b8db1f5ef0d8f65ffbee92b8992c9686e91`

### Claims and source pins

#### Headline

Nesiritide: the clinical experience. ([`pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302`](#source-pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302))

#### Summary

PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302`](#source-pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302))

#### Paragraph 1

PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302`](#source-pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302`](#source-pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302))

### Sources

<a id="source-pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302"></a>
- **Nesiritide: the clinical experience. · retained source version 1:2026-05-13:current:2117b2bb63027345973b5181ed917962be4a0c19f504818059139915aadd9695** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18629384/) (`pubmed-observation-pmid-18629384-2026-05-13-2117b2bb6302`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide: the clinical experience." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18629384-nesiritide-v1 SHA-256: 9b657e716776beeb08fff90d97ae1b8db1f5ef0d8f65ffbee92b8992c9686e91.

---

<a id="pubmed-pmid-18833867-nesiritide-v1"></a>

## Nesiritide in the initial management of acute decompensated congestive heart failure.

> PubMed lists PMID 18833867 in Connecticut medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18833867-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2008-10-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18833867-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18833867-nesiritide-v1
- Content SHA-256: `846f84b21e3f812a3b579a5fd7a90f3074377e99cfe60c64284cee28c2befe94`

### Claims and source pins

#### Headline

Nesiritide in the initial management of acute decompensated congestive heart failure. ([`pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec`](#source-pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec))

#### Summary

PubMed lists PMID 18833867 in Connecticut medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec`](#source-pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec))

#### Paragraph 1

PubMed lists PMID 18833867 in Connecticut medicine as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec`](#source-pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec`](#source-pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec))

### Sources

<a id="source-pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec"></a>
- **Nesiritide in the initial management of acute decompensated congestive heart failure. · retained source version 1:2008-10-06:current:8c3561e5f9ecea73d1bbdd95a5e96dc3d504845bc1557ae5a11e3aee25879244** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18833867/) (`pubmed-observation-pmid-18833867-2008-10-06-8c3561e5f9ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide in the initial management of acute decompensated congestive heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18833867-nesiritide-v1 SHA-256: 846f84b21e3f812a3b579a5fd7a90f3074377e99cfe60c64284cee28c2befe94.

---

<a id="pubmed-pmid-18928481-nesiritide-v1"></a>

## Nesiritide following maze and mitral valve surgery.

> PubMed lists PMID 18928481 in Journal of cardiac surgery as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18928481-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18928481-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18928481-nesiritide-v1
- Content SHA-256: `a1f1d4de3f644809dff6d8600653275dee8907eae464f901dc44f612c7f6fe76`

### Claims and source pins

#### Headline

Nesiritide following maze and mitral valve surgery. ([`pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f`](#source-pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f))

#### Summary

PubMed lists PMID 18928481 in Journal of cardiac surgery as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f`](#source-pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f))

#### Paragraph 1

PubMed lists PMID 18928481 in Journal of cardiac surgery as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f`](#source-pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f`](#source-pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f))

### Sources

<a id="source-pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f"></a>
- **Nesiritide following maze and mitral valve surgery. · retained source version 1:2025-04-28:current:19b3ba5c784f1ca5520a4bc05a0cd8ebeb2509dce442d4e4fecf8caad4fab431** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18928481/) (`pubmed-observation-pmid-18928481-2025-04-28-19b3ba5c784f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide following maze and mitral valve surgery." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18928481-nesiritide-v1 SHA-256: a1f1d4de3f644809dff6d8600653275dee8907eae464f901dc44f612c7f6fe76.

---

<a id="pubmed-pmid-18953274-nesiritide-v1"></a>

## Nesiritide in acute decompensated heart failure: current status and future perspectives.

> PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18953274-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18953274-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18953274-nesiritide-v1
- Content SHA-256: `acd234fc8d49cb30cd399019dcfa1459c2db3006b50e249709eb3a19469e4f7a`

### Claims and source pins

#### Headline

Nesiritide in acute decompensated heart failure: current status and future perspectives. ([`pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd`](#source-pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd))

#### Summary

PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd`](#source-pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd))

#### Paragraph 1

PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd`](#source-pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd`](#source-pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd))

### Sources

<a id="source-pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd"></a>
- **Nesiritide in acute decompensated heart failure: current status and future perspectives. · retained source version 1:2026-11-08:current:14b54a2667cdcb3ee4f799922c47915ae439db4b1a89b5eb7c4ac942b8bb61f8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18953274/) (`pubmed-observation-pmid-18953274-2026-11-08-14b54a2667cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide in acute decompensated heart failure: current status and future perspectives." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-18953274-nesiritide-v1 SHA-256: acd234fc8d49cb30cd399019dcfa1459c2db3006b50e249709eb3a19469e4f7a.

---

<a id="pubmed-pmid-19538002-nesiritide-v1"></a>

## The role of nesiritide in heart failure.

> PubMed lists PMID 19538002 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-19538002-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-07-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19538002-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-19538002-nesiritide-v1
- Content SHA-256: `e8e738377f8af2cda1b308ad84a9426681626ecf81ef7b9800165b1b877df0f6`

### Claims and source pins

#### Headline

The role of nesiritide in heart failure. ([`pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac`](#source-pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac))

#### Summary

PubMed lists PMID 19538002 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac`](#source-pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac))

#### Paragraph 1

PubMed lists PMID 19538002 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac`](#source-pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac`](#source-pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac))

### Sources

<a id="source-pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac"></a>
- **The role of nesiritide in heart failure. · retained source version 1:2014-07-30:current:13061a6f61ac92b1dcbaed64319dae36c651e96a89a7614b6d025410db53ec89** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19538002/) (`pubmed-observation-pmid-19538002-2014-07-30-13061a6f61ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The role of nesiritide in heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-19538002-nesiritide-v1 SHA-256: e8e738377f8af2cda1b308ad84a9426681626ecf81ef7b9800165b1b877df0f6.

---

<a id="pubmed-pmid-25853935-nesiritide-v1"></a>

## Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.

> PubMed lists PMID 25853935 in The American journal of the medical sciences as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25853935-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25853935-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-25853935-nesiritide-v1
- Content SHA-256: `9019a24a05af52dc0671afb7790ba2646c2797063c347f961d2babb8407ceea9`

### Claims and source pins

#### Headline

Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. ([`pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c`](#source-pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c))

#### Summary

PubMed lists PMID 25853935 in The American journal of the medical sciences as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c`](#source-pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c))

#### Paragraph 1

PubMed lists PMID 25853935 in The American journal of the medical sciences as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c`](#source-pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c`](#source-pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c))

### Sources

<a id="source-pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c"></a>
- **Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. · retained source version 1:2018-12-02:current:eb1a84b3f01cd54ef5ccf1a8d35bda357b1077d90569b5d87035811382e1758c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25853935/) (`pubmed-observation-pmid-25853935-2018-12-02-eb1a84b3f01c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Levosimendan and nesiritide as a combination therapy in patients with acute heart failure." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-25853935-nesiritide-v1 SHA-256: 9019a24a05af52dc0671afb7790ba2646c2797063c347f961d2babb8407ceea9.

---

<a id="pubmed-pmid-26028173-nesiritide-v1"></a>

## Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.

> PubMed lists PMID 26028173 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2015-05-31 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26028173-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-06-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26028173-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-26028173-nesiritide-v1
- Content SHA-256: `4e73069c57c62cad6179f6b2e643f2fab46d2ee412e00a637208e2e2e950d6e8`

### Claims and source pins

#### Headline

Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials. ([`pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405`](#source-pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405))

#### Summary

PubMed lists PMID 26028173 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2015-05-31 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405`](#source-pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405))

#### Paragraph 1

PubMed lists PMID 26028173 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2015-05-31 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405`](#source-pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405`](#source-pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405))

### Sources

<a id="source-pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405"></a>
- **Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials. · retained source version 1:2015-06-25:current:fb5a46083405c058ab88f860e8552d8e0c42570ec335841a2d6b814f75e9c507** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26028173/) (`pubmed-observation-pmid-26028173-2015-06-25-fb5a46083405`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-26028173-nesiritide-v1 SHA-256: 4e73069c57c62cad6179f6b2e643f2fab46d2ee412e00a637208e2e2e950d6e8.

---

<a id="pubmed-pmid-31948318-nesiritide-v1"></a>

## Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis.

> PubMed lists PMID 31948318 in The Journal of international medical research as Journal Article, Meta-Analysis, with publication-date metadata of 2020-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31948318-nesiritide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-11-17
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31948318-nesiritide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-31948318-nesiritide-v1
- Content SHA-256: `b5fce9c51bc6aa69b52998591125868350988d93c87f5cffcf9187d06e9d8e61`

### Claims and source pins

#### Headline

Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis. ([`pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe`](#source-pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe))

#### Summary

PubMed lists PMID 31948318 in The Journal of international medical research as Journal Article, Meta-Analysis, with publication-date metadata of 2020-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe`](#source-pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe))

#### Paragraph 1

PubMed lists PMID 31948318 in The Journal of international medical research as Journal Article, Meta-Analysis, with publication-date metadata of 2020-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe`](#source-pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe`](#source-pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe))

### Sources

<a id="source-pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe"></a>
- **Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis. · retained source version 1:2020-11-17:current:9e4a6634dcbe6b3d8d8abe9e7d7534a19ca5fa8b46e78ab732c77428adeea766** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31948318/) (`pubmed-observation-pmid-31948318-2020-11-17-9e4a6634dcbe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/nesiritide.json#pubmed-pmid-31948318-nesiritide-v1 SHA-256: b5fce9c51bc6aa69b52998591125868350988d93c87f5cffcf9187d06e9d8e61.

